Epiminder Ltd (ASX:EPI) Share Price & Analysis

Epiminder Limited (ASX: EPI) is a Melbourne-based medical technology company specializing in the development of neurological monitoring solutions for drug-resistant epilepsy. Established in 2018 through a collaboration between the Bionics Institute, the University of Melbourne, St Vincent’s Hospital, and Cochlear Limited, the company was admitted to the official list of the Australian Securities Exchange in late 2025. Its operations center on the design and commercialization of long-term, sub-scalp electroencephalography (EEG) systems intended to provide objective data for clinical seizure management.

The company’s primary asset is the Minder system, an implantable device engineered to continuously monitor brain activity and record electrographic data over extended periods. Unlike conventional scalp-based EEG systems that are typically restricted to short-term diagnostic use, the Minder device is implanted under the scalp to facilitate continuous monitoring for up to three years. Epiminder utilizes Cochlear’s established manufacturing capabilities for its hardware components while developing proprietary software platforms to analyze recorded data and generate actionable clinical insights for healthcare professionals and patients.

Epiminder maintains a strategic focus on the global epilepsy market, with significant operational emphasis on the United States following FDA authorization of its monitoring technology. The company is currently conducting its “DETECT” demonstration program to validate clinical utility and support reimbursement initiatives, targeting the substantial population of patients with refractory epilepsy. By delivering continuous, real-world neurological data, Epiminder seeks to replace subjective patient reporting methods and enhance the standard of care for chronic neurological conditions through data-driven treatment optimization.